Device Trial Radar · NCT01116037
ATS 3f(r) Aortic Bioprosthesis Model 1000 Post Approval Study
Last checked: Nov 20, 2026Latest source record: May 25, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
26
Actual
Start
Sep 2009
Primary completion
Nov 2015
Study completion Nov 2015
Sponsor
- Lead sponsor
- Medtronic CardiovascularPublic (MDT)
- Sponsor type
- Industry
- First posted
- May 4, 2010
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical study is to determine if there is an increased incidence and rate of aortic regurgitation in younger (\</= 70 years of age) patients implanted with the Model 1000 and undergoing isolated aortic valve replacement of his/her native aortic valve, or replacement of a failed prosthesis.
Conditions
- Heart Valve Diseases
Interventions
ATS 3f Aortic BioprosthesisDevice
Equine Pericardial Bioprosthesis for replacement of diseased valve
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Efficacy Goal is to Assess the Freedom From Clinically Significant (Moderate or Greater) Aortic Regurgitation for the Patients Implanted With 3f Aortic Bioprothesis, Model 1000Time frame: Six Years
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
Cardiac Surgery Clinical Research Center, Inc.
Oak Lawn, Illinois
Columbia University
New York, New York
Univ of Pennsylvania Medical Center
Philadelphia, Pennsylvania
3 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.